Ai Vivo
AI VIVO (AIVIVO LTD) is a Cambridge, England based drug-discovery company that combines systems pharmacology with artificial intelligence to accelerate the identification and de-risking of therapeutic candidates. Its "Organome" platform simulates biological processes at the target, cell, organ, and organism levels and ranks drug candidates by their phenotypic effects at the tissue level, without relying on prior knowledge of the disease or compounds. The approach gained recognition in 2020 when the platform ranked roughly 90,000 compounds for COVID-19 and surfaced dexamethasone as a top candidate weeks before its clinical benefit was widely reported. AI VIVO is backed by DCVC and other life-science and applied-AI investors. As of this profile the company publishes a minimal public web presence (a home and contact page) and exposes no public developer API, documentation, or SDK.
Ai Vivo is profiled on the APIs.io network. Tagged areas include Company, Artificial Intelligence, Drug Discovery, Systems Pharmacology, and Biotechnology.
Kin Score
Resources
Operate 1
Status, limits, changes, and where to get help
Company 1
The organization behind the API